Semaglutide and obesity: a systematic review workflow example
This semaglutide systematic review example shows how a focused obesity question can move through search boundaries, eligibility decisions, an evidence table, a structured synthesis, and citation checks. It is a workflow demonstration, not a peer-reviewed or complete clinical systematic review.
Start with this questionResearch question
What does current evidence suggest about semaglutide for weight loss in adults with obesity?
Search boundary and screening
- Natural-language question expanded into semaglutide, obesity, weight loss, adults, GLP-1 receptor agonist, randomized trial, and safety terms.
- Candidate records are screened at title and abstract level before inclusion in the public synthesis preview.
- The preview labels full-text appraisal, protocol registration, and meta-analysis as outside this example.
48
Identified
24
Screened
8
Included
16
Excluded
- Excluded non-adult populations and papers not focused on obesity outcomes.
- Prioritized trials and review articles with explicit weight and safety endpoints.
- Marked long-term maintenance claims for human verification.
Included evidence
The evidence table keeps study context visible before synthesis.
| Citation | Study | Population | Finding | Support |
|---|---|---|---|---|
| STEP-style randomized trial evidence | Randomized controlled trial | Adults with overweight or obesityLarge multicenter trial population | Semaglutide groups reported greater mean weight reduction than lifestyle-only comparators. | strong |
| Safety and tolerability analysis | Trial safety analysis | Adults receiving GLP-1 receptor agonist therapyPooled adverse event observations | Gastrointestinal adverse events are prominent and discontinuation context should be reported. | moderate |
| Weight maintenance follow-up | Follow-up study | Adults after treatment continuation or withdrawalLonger follow-up cohort | Durability claims depend on treatment continuation, follow-up duration, and behavioral support. | needs review |
Synthesis preview
What the selected evidence says
This public preview illustrates how LitSynth structures a PRISMA-lite review on semaglutide for adults with obesity. The report separates search and screening assumptions from synthesis claims, groups findings into efficacy, safety, and durability sections, and marks clinical statements that require original-paper verification before use. It is intentionally presented as a review preview, not medical advice or a completed systematic review.
Citation support check
Efficacy statements are well supported in this preview; durability and comparative safety claims require closer source inspection.
9 strongly supported claims · 3 need review
Method limits
- Treating this example as a peer-reviewed clinical conclusion
- Replacing a formal systematic review or clinical guidance
Use the workflow behind this example
Recreate this workflow with your own evidence
Open the editable review workflow with this question, then change the scope, papers, or inclusion decisions.
Start with this question